Myeloid-derived suppressor cells in hematological malignancies: friends or foes
TL;DR: This review will help researchers better understand the various characteristics and functions of MDSCs, as well as the potential therapeutic applications of M DSCs in hematological malignancies, including lymphoma, multiple myeloma, leukemia, and hematopoietic stem cell transplantation.
read more
Abstract: Myeloid-derived suppressor cells (MDSCs) are newly identified immature myeloid cells that are characterized by the ability to suppress immune responses and expand during cancer, infection, and inflammatory diseases. Although MDSCs have attracted a lot of attention in the field of tumor immunology in recent years, little is known about their multiple roles in hematological malignancies as opposed to their roles in solid tumors. This review will help researchers better understand the various characteristics and functions of MDSCs, as well as the potential therapeutic applications of MDSCs in hematological malignancies, including lymphoma, multiple myeloma, leukemia, and hematopoietic stem cell transplantation.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies
TL;DR: Targeting the regulation of HMGB1 activity in HSCs and the BM microenvironment is highly beneficial in the diagnosis and treatment of various hematopoietic malignancies.
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment.
TL;DR: A comprehensive review of lipid metabolism dysfunction in the tumor microenvironment and its dual effects on the immune response is provided in this paper, which is critical for mapping the detailed landscape of tumor immunology and developing specific treatments for cancer patients.
144
Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
Qitai Zhao,Lan Huang,Guohui Qin,Yamin Qiao,Feifei Ren,Chunyi Shen,Shumin Wang,Shasha Liu,Jinyao Lian,Dan Wang,Weina Yu,Yi Zhang +11 more
TL;DR: In this paper, the authors observed that monocytic myeloid-derived suppressor cells (MDSCs) were correlated with cisplatin resistance in patients with esophageal squamous cell carcinoma (ESCC).
113
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
TL;DR: The role of MDSCs in resistance to ICIs is focused, therapeutic strategies targeting them to enhance ICIs efficiency in cancer patients are summarized and a potential therapy to overcome the limitation is considered.
Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs.
Jérôme Mastio,Thomas Condamine,George A. Dominguez,Andrew V. Kossenkov,Laxminarasimha Donthireddy,Filippo Veglia,Cindy Lin,Fang Wang,Shuyu Fu,Shuyu Fu,Jie Zhou,Patrick Viatour,Sergio Lavilla-Alonso,Alexander Polo,Evgenii N. Tcyganov,Charles Mulligan,Brian Nam,Joseph J. Bennett,Gregory A. Masters,Michael J. Guarino,Amit Kumar,Yulia Nefedova,Robert H. Vonderheide,Lucia R. Languino,Scott I. Abrams,Dmitry I. Gabrilovich +25 more
TL;DR: These precursors are barely detectable in steady state conditions and are not consequential for differentiation of granulocytes, but they accumulate in cancer and substantially contribute to PMN-MDSC expansion.
References
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Bastian Hoechst,Lars A. Ormandy,Matthias Ballmaier,Frank Lehner,Christine Krüger,Michael P. Manns,Tim F. Greten,Firouzeh Korangy +7 more
TL;DR: A new mechanism by which myeloid-derived suppressor cells exert their immunosuppressive function is proposed, through the induction of CD4(+)CD25(+)Foxp3(+) regulatory T cells in cocultured CD 4(+) T cells.
827
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini,Kristen Meckel,Michael Kelso,Kimberly A. Noonan,Joseph A. Califano,Wayne M. Koch,Luigi Dolcetti,Vincenzo Bronte,Ivan Borrello +8 more
TL;DR: In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive mechanisms and enables a measurable antitumor immune response to be generated that substantially delays tumor progression.
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Cesar A. Corzo,Matthew J. Cotter,Pingyan Cheng,Fendong Cheng,Sergei Kusmartsev,Eduardo M. Sotomayor,Tapan A. Padhya,Thomas V. McCaffrey,Judith C. McCaffrey,Dmitry I. Gabrilovich +9 more
TL;DR: A substantial up-regulation of ROS by MDSC is observed in all of seven different tumor models and in patients with head and neck cancer, mediated by up-regulated activity of NADPH oxidase (NOX2) and may open new opportunities for therapeutic regulation of these cells in cancer.
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
Pratima Sinha,Chinonyerem Okoro,Dirk Foell,Hudson H. Freeze,Suzanne Ostrand-Rosenberg,Geetha Srikrishna +5 more
TL;DR: It is shown that this population of immature myeloid cells induced by a given tumor share a common phenotype regardless of their in vivo location, and that Gr1highCD11bhighF4/80−CD80+IL4Rα+/−Arginase+ MDSC are induced by the proinflammatory proteins S100A8/A9.
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.
TL;DR: A role is established for myeloid-derived suppressor cells (MDSC) in antigen-specific tolerance induction through preferential antigen uptake mediating the recruitment and expansion of Tregs.
703